COMPASS Pathways to participate in three upcoming investor events Post published:September 1, 2022 Post category:Press Release
Optimi Health Provides Progress Report On Year Of Commercialization Post published:September 1, 2022 Post category:Press Release
FILAMENT HEALTH AND ATMA JOURNEY CENTERS ANNOUNCE 14 SUBJECTS DOSED IN HEALTH CANADA-APPROVED PSILOCYBIN CLINICAL TRIAL Post published:September 1, 2022 Post category:Press Release
Reunion Neuroscience Inc. Announces 2022 Annual General Meeting of Shareholders Post published:September 1, 2022 Post category:Press Release
Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome Post published:August 31, 2022 Post category:Press Release
Mindset Pharma Further Expands its IP Portfolio with Three Additional Non-Tryptamine Families of Next-Generation Psychedelic Compounds Post published:August 31, 2022 Post category:Press Release
Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022 Post published:August 31, 2022 Post category:Press Release
Optimi Health Enters Into International Collaborative Research and Supply Agreement With Promises Innovative Recovery Center Post published:August 31, 2022 Post category:Press Release
Bright Minds Biosciences Announces Closing of $4 Million Unit Offering Post published:August 31, 2022 Post category:Press Release
Mindset Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022 Post published:August 30, 2022 Post category:Press Release